aTyr Pharma, Inc.
ATYR
$3.99
$0.4412.39%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -97.81% | -94.34% | -94.34% | -96.60% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.81% | -94.34% | -94.34% | -96.60% | -- |
| Cost of Revenue | 23.51% | 14.58% | 6.90% | -1.20% | 31.30% |
| Gross Profit | -62.16% | -48.24% | -38.85% | -29.36% | 0.43% |
| SG&A Expenses | 1.42% | -10.40% | -5.97% | -7.17% | -0.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.45% | 8.49% | 3.77% | -2.67% | 22.41% |
| Operating Income | -45.07% | -30.84% | -25.54% | -18.35% | 0.39% |
| Income Before Tax | -47.86% | -28.48% | -19.47% | -11.15% | 6.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.86% | -28.48% | -19.47% | -11.15% | 6.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -111.11% | -112.50% | -40.00% | 60.00% | 80.00% |
| Net Income | -47.89% | -28.51% | -19.48% | -11.14% | 6.96% |
| EBIT | -45.07% | -30.84% | -25.54% | -18.35% | 0.39% |
| EBITDA | -44.97% | -30.26% | -24.68% | -17.66% | 0.72% |
| EPS Basic | 2.73% | 26.38% | 37.64% | 40.38% | 41.62% |
| Normalized Basic EPS | 2.72% | 26.38% | 37.64% | 40.37% | 41.61% |
| EPS Diluted | 3.19% | 26.66% | 37.84% | 40.55% | 41.34% |
| Normalized Diluted EPS | 2.72% | 26.38% | 37.64% | 40.37% | 41.61% |
| Average Basic Shares Outstanding | 48.57% | 65.04% | 86.61% | 88.44% | 63.83% |
| Average Diluted Shares Outstanding | 48.57% | 65.04% | 86.61% | 88.44% | 63.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
